Voclosporin
FDA approves updated label for Lupkynis with long-term data, new monitoring guidelines
The FDA has approved an updated label for Lupkynis, an oral treatment for active lupus nephritis, that includes long-term safety and tolerability data, and eases the requirement for monthly kidney function assessments.
Voclosporin exhibits positive long-term safety, efficacy data over 3 years
Long-term voclosporin is safe and efficacious for the treatment of lupus nephritis over 3 years, according to data published in Arthritis & Rheumatology.
‘A very exciting time’: Voclosporin, cell therapies represent future of lupus treatment
SAN DIEGO —The recent voclosporin approval and continued research into cell therapies make this a “very exciting time” for lupus nephritis therapy, according to a speaker 2023 Congress of Clinical Rheumatology West.
Tacrolimus shows promise in treatment of dermatologic conditions with risk factors
Compared with the systemic calcineurin inhibitor standard cyclosporine, tacrolimus shows promise for numerous dermatologic conditions, whereas the literature on voclosporin is limited, according to a study.
VIDEO: Voclosporin seen as well tolerated in patients with lupus nephritis for 3 years
ORLANDO — In this video from ASN Kidney Week, Samir V. Parikh, MD, discusses the results of the AURORA 2 study.
Patients with lupus ‘not doing as well as we would like’ despite new therapies
SAN DIEGO — New drugs for the management of systemic lupus erythematosus and lupus nephritis may help bridge the gap of current unmet needs among patients, according to a speaker at the Congress of Clinical Rheumatology West.
‘Comfort level’ driving divide between rheumatologists, nephrologists in lupus nephritis
Recent data has revealed a growing divide between rheumatologists and nephrologists in their therapeutic choices for patients with lupus nephritis, according to researchers from Spherix Global Insights.
Q&A: CD6/ALCAM may hold key to more specific, effective therapies in lupus nephritis
Uncovering a viable biomarker in a historically challenging disease like lupus nephritis is tantamount to striking gold if it can be used for one important purpose: Predicting treatment response.